limiting toxicity

Related by string. * limited . limits . Limits . Limiting . LIMITED . limiter : Limited Brands Inc. . Holdings Limited . Flow Through Limited . Limited Late Model . INCLUDING BUT NOT LIMITED / Toxicity . TOXICITY : hematologic toxicity correlated . mitochondrial toxicity . systemic toxicity . renal toxicity . hematologic toxicity * limiting toxicity DLT . Dose Limiting Toxicity DLT *

Related by context. All words. (Click for frequent words.) 79 dose limiting toxicities 75 DLTs 71 hematologic toxicity 70 limiting toxicity DLT 68 tolerated dose MTD 68 maximal tolerated 68 neutropenia dehydration dyspnea 67 hypercalcemia 67 lymphopenia 66 cytopenias 66 myelosuppression 66 Bezielle 66 nephrotoxicity 66 alvespimycin 66 elevated ALT 65 Hepatotoxicity 65 achieved statistical significance 65 neutropenia thrombocytopenia 65 Toxicities 65 posaconazole 65 CIMZIA ™ 65 anti leukemic 65 PREZISTA r 65 QTc prolongation 65 ganetespib 65 severe hypersensitivity reactions 65 CIMZIA TM 65 Seliciclib 65 pyrexia mucositis sepsis febrile 65 pharmacokinetic interactions 65 HGS ETR1 65 selective modulator 65 APTIVUS r 65 ispinesib administered 65 hematological toxicity 64 hypomagnesemia 64 estramustine 64 hepatotoxicity 64 INCB# [003] 64 events SAEs 64 myeloproliferative diseases 64 refractory NSCLC 64 endothelin receptor antagonists 64 velafermin 64 hematologic adverse 64 Pralatrexate 64 CTAP# Capsules 64 myopathy rhabdomyolysis 64 MAGE A3 ASCI 64 oral prodrug 64 FOLPI 64 relapsed MM 64 neutropaenia 64 cisplatin gemcitabine 64 maximally tolerated dose 64 adecatumumab 64 refractory AML 64 heavily pretreated 64 antitumor activity 64 PRT# 64 elotuzumab 64 nab paclitaxel 64 renal toxicity 63 TNF blocker therapy 63 morphometric vertebral fractures 63 tumor lysis syndrome 63 desvenlafaxine succinate 63 GSK# [001] 63 nonhematologic adverse reactions 63 pharmacodynamic PD 63 ara C 63 stage IIIB 63 peripheral sensory neuropathy 63 Fibrillex TM 63 ACTEMRA TM 63 thromboembolic events 63 mcg BID 63 DOXIL 63 haematologic 63 Bortezomib 63 imatinib therapy 63 mGluR5 NAM 63 EDEMA3 trial 63 HBeAg seroconversion 63 virologic failure 63 laboratory abnormalities 63 non hematological toxicities 63 CA4P 63 Voreloxin 63 INC# 63 Myelosuppression 63 MCyR 63 tolvaptan 63 Ophena TM 63 VAPRISOL 63 cytogenetic response 63 PEG Interferon lambda 63 CYT# potent vascular disrupting 63 mg TID 63 recurrent glioblastoma multiforme 63 pomalidomide 63 idarubicin 63 TEAEs 63 thrombocytopenia neutropenia 63 dosage regimens 63 toxicities 62 tanespimycin 62 temsirolimus 62 dextromethorphan quinidine 62 evaluating tivozanib 62 pharmacokinetic equivalence 62 TORISEL 62 viral kinetics 62 fosbretabulin 62 GOUT 62 Xanafide 62 pertuzumab 62 K ras mutations 62 cardiac toxicity 62 peginterferon alfa 62 refractory gout 62 mg/m2 dose 62 riociguat 62 receptor tyrosine kinase inhibitor 62 PEGylated anti 62 GMX# 62 PXD# 62 tipranavir 62 composite endpoint 62 CR nPR 62 refractory multiple myeloma 62 #mg/m# [001] 62 pulmonary exacerbations 62 ISTODAX 62 docetaxel chemotherapy 62 HMG CoA reductase inhibitors 62 serum phosphate 62 systemically administered 62 gemcitabine Gemzar ® 62 Entereg R 62 PSMA ADC 62 Pegasys ® 62 alfa 2a 62 huC# DM4 62 PEGylated interferon beta 1a 62 plasma kallikrein inhibitor 62 ALT flares 62 dexpramipexole 62 dasatinib Sprycel ® 62 discontinuations due 62 Aztreonam lysine 62 Pharmacokinetic parameters 62 FOLFOX6 62 favorable pharmacokinetic profile 62 Gemzar ® 62 orally administered inhibitor 62 febrile neutropenia 62 preclinically 62 overlapping toxicities 62 FOLFIRI 62 CR# vcMMAE 62 tolerability profiles 62 gastrointestinal toxicities 61 Glufosfamide 61 dose escalation 61 interferon alfa 2b 61 alpha interferons 61 INCB# [001] 61 TNF Tumor Necrosis Factor 61 demonstrated antitumor activity 61 HuMax EGFr 61 Adalimumab 61 Telintra 61 virologic responses 61 Azixa 61 AST ALT 61 coadministration 61 OADs 61 mapatumumab 61 HBeAg positive patients 61 Thrombocytopenia 61 lenalidomide dexamethasone 61 interferon alfa 61 hematological adverse 61 virologic response 61 transaminase elevations 61 Panzem R NCD 61 COPEGUS 61 Phenoptin 61 ribavirin RBV 61 clinically meaningful reductions 61 plus prednisone prednisolone 61 8mg/kg 61 virologic breakthrough 61 vandetanib 61 BENICAR HCT 61 sitaxsentan 61 TELCYTA 61 heparin induced thrombocytopenia 61 genotypic resistance 61 serum phosphorous 61 hematological toxicities 61 mocetinostat 61 thrombocytopenia 61 salmeterol HFA MDI 61 novel VDA molecule 61 R# #mg BID 61 PEG SN# 61 dasatinib 61 mcg kg 61 GLYX 61 SPRYCEL ® 61 plasma pharmacokinetics 61 CCyR 61 PROMACTA 61 sunitinib Sutent ® 61 voreloxin 61 Phase 2a trial 61 Ceplene/IL-2 61 ribavirin therapy 61 pharmacokinetic parameters 61 mg BID 61 mg kg dose 61 galiximab 61 recurrent genital herpes 61 vidofludimus 61 Omacetaxine 61 EGFR TKI 61 carcinoid syndrome 61 relapsed SCLC 61 MAP# 61 APOPTONE 61 Phase Ib study 61 intravascular hemolysis 61 Monotherapy 61 anemia neutropenia 61 liposomal formulation 61 leukopenia 61 prospectively defined 61 erythropoietic 61 PegIFN RBV 61 telaprevir dosed 61 AGILECT R 61 HES CEL 61 CCX# 61 Primary endpoints 61 PREZISTA r arm 61 dose proportionality 61 motesanib 61 Perifosine 61 cangrelor 61 erlotinib Tarceva ® 61 CIMZIA TM certolizumab pegol 61 Non inferiority 61 EOquin 60 insulin detemir 60 MGCD# MGCD# [001] 60 LHRH antagonists 60 Elotuzumab 60 virological response 60 Febrile neutropenia 60 liver transaminases 60 ARIKACE ™ 60 complete cytogenetic response 60 plus COPEGUS 60 urocortin 2 60 myelofibrosis polycythemia vera 60 Triapine R 60 melphalan prednisone 60 Doxil ® 60 teriflunomide 60 secondary efficacy endpoints 60 Methylnaltrexone 60 forodesine 60 ENMD # 60 TACI Ig 60 EDEMA4 trial 60 Cloretazine R VNP#M 60 4mg/kg 60 events AEs 60 tocilizumab 60 Archexin 60 CR CRu 60 EXJADE 60 strong CYP#A# inducers 60 ELACYT 60 proteasome inhibitor 60 administered concomitantly 60 CYP#A# CYP#D# 60 Dasatinib 60 BEXXAR Therapeutic Regimen 60 NNRTI resistance 60 valopicitabine 60 invasive aspergillosis 60 neurologic progression 60 pruritus itching 60 alkylating agent 60 gemifloxacin 60 2 methoxyestradiol 60 BRIM2 60 LEP ETU 60 HCV SPRINT 60 chemotherapy induced neutropenia 60 Valortim R 60 hyperphenylalaninemia HPA due 60 PKC# 60 lopinavir r arm 60 leukemia AML 60 HGS ETR1 mapatumumab 60 obatoclax 60 Genasense ® 60 TMC# [002] 60 sorafenib Nexavar ® 60 interferon beta therapy 60 CIMZIA R 60 Pemetrexed 60 SVR# 60 ARIKACE 60 daunorubicin 60 rapid virologic response 60 HER2 positive metastatic breast 60 Darinaparsin 60 PEGylated Fab fragment 60 corticosteroid therapy 60 uric acid lowering 60 seliciclib 60 tolerability 60 intravenous bisphosphonates 60 headache nasopharyngitis 60 Cariprazine 60 dacetuzumab 60 HER2 overexpression 60 Antitumor Activity 60 palonosetron 60 ADAGIO study 60 docetaxel Taxotere ® 60 lipid parameters 60 IMGN# 60 MGCD# [002] 60 clinically meaningful improvement 60 sustained virological response 60 #D#C# 60 autoimmune reactions 60 imetelstat 60 octreotide LAR 60 NGX# 60 pharmacodynamic effects 60 efficacy endpoint 60 ANAVEX #-# [001] 60 Maximum Tolerated Dose MTD 60 pathophysiological effects 60 vinorelbine 60 rFVIIa 60 talactoferrin 60 Fulvestrant 60 RAPAFLO R 60 moderate renal impairment 60 noninferiority 60 non nucleoside HCV 60 Zerenex 60 CANCIDAS 60 Tolvaptan 60 dosing cohorts 60 hemorrhagic complications 60 inhibitor RG# 60 STRIDE PD 60 Teriflunomide 60 mRCC 60 Elesclomol 60 canakinumab 60 oral olanzapine 60 PRTX 60 intracranial hemorrhage ICH 60 optimal dosing 60 telbivudine 60 sorafenib Nexavar 60 clinically meaningful differences 60 vismodegib 60 metastatic GIST 60 KRAS status 60 torsemide ER 60 Virulizin ® 60 superficial bladder cancer 60 dimebon 60 histologies 60 immunomodulatory therapy 60 Exelixis XL# 60 urate lowering 60 teduglutide 60 OMNARIS HFA 59 Cmax 59 Golimumab 59 TELINTRA 59 chlorambucil 59 sJIA 59 febuxostat 59 UPLYSO 59 venlafaxine XR 59 ZOLINZA 59 squalamine 59 dacarbazine 59 relapsed multiple myeloma 59 plus methotrexate 59 reactogenicity 59 neurotoxicity 59 HCV protease 59 annualized relapse 59 dose cohort 59 JANUVIA 59 ritonavir boosted 59 XL# anticancer compounds 59 cell lymphoma CTCL 59 EDEMA3 59 definite stent thrombosis 59 hematologic toxicities 59 patients coinfected 59 hepatic dysfunction 59 PASI scores 59 trastuzumab Herceptin R 59 alicaforsen enema 59 FOLFOX4 59 ELND# 59 granisetron 59 Neutropenia 59 pegylated liposomal doxorubicin 59 YONDELIS 59 salmeterol fluticasone 59 Darusentan 59 sustained virologic response 59 6R BH4 59 achieved ACR# 59 efalizumab 59 MEND CABG II 59 pharmacokinetic PK study 59 hypersensitivity reaction 59 certolizumab pegol 59 FluCAM arm 59 Phase Ib II 59 pancytopenia 59 oral ridaforolimus 59 aflibercept VEGF Trap 59 oblimersen 59 Hypotension 59 MYCAMINE 59 investigational monoclonal antibody 59 Tolerability 59 phase IIb clinical 59 ARCALYST ® 59 pharmacodynamic parameters 59 platinum refractory 59 mycophenolate mofetil 59 favorable tolerability 59 PS# [001] 59 ALB # 59 immunomodulation 59 NPH insulin 59 patients receiving ERBITUX 59 Dapagliflozin 59 Pivotal Phase III 59 C1 INH 59 TTF Therapy 59 bone marrow suppression 59 Azedra 59 Vidofludimus 59 RSD# oral 59 discontinuations 59 adalimumab 59 urinary N telopeptide 59 AEGR 59 tigecycline 59 MET amplification 59 neutropenia febrile neutropenia 59 mertansine 59 leucopenia 59 HGS ETR2 59 lactate dehydrogenase LDH 59 VP# [004] 59 evaluable patients 59 FUSILEV enhances 59 systemic absorption 59 pimozide 59 lispro 59 Hematologic toxicity 59 FFNS 59 refractory cutaneous T 59 zonisamide SR 59 phase Ib 59 pericardial effusion 59 Ambrisentan 59 Triolex 59 Maximum Tolerated Dose 59 vaccine RiVax TM 59 aplindore 59 FOLPI regimen 59 hematological parameters 59 nalbuphine ER 59 Eltrombopag 59 TNFalpha 59 AP# [003] 59 INVEGA ® 59 GEMZAR 59 KRN# 59 Certolizumab 59 TYKERB 59 CDK inhibitor 59 brivaracetam 59 ULORIC 59 EGFR HER2 59 apoptosis inducer 59 sorafenib tablets 59 Oral corticosteroids 59 Omacetaxine mepesuccinate 59 peginterferon 59 glufosfamide 59 bortezomib 59 IIa trial 59 visilizumab 59 MGd 59 HCV RESPOND 2 59 mcg mL 59 unique alkylating agent 59 treatment emergent adverse 59 ACR# responses 59 Phase Ib 59 Amrubicin 59 certolizumab 59 REBETOL therapy 59 SILENOR TM 59 cilengitide 59 ZACTIMA 59 locoregional recurrence 59 imatinib resistant 59 rHuPH# 59 pharmacokinetics PK 59 hypercholesterolemic patients 59 antiretroviral naive 59 TLUS 59 azacitidine 59 pCR 59 ALVESCO 59 #mg/day [002] 59 Symadex 59 JAK inhibitor 59 NATRECOR ® 59 dermatologic toxicities 59 IMC A# 59 axitinib 59 blinded randomized placebo controlled 59 Fludara 59 leukopenia pancytopenia thrombocytopenia 59 cabazitaxel 59 complete remissions 59 Aflibercept 59 aplastic anemia AA 59 #mg BID [003] 59 OXi# 59 plus gemcitabine 59 bendamustine 59 albiglutide 59 VELCADE melphalan 59 LY# [003] 59 clinical trials alitretinoin 59 bezafibrate 59 Lactic acidosis 59 quetiapine XR 59 paliperidone ER 59 amprenavir 59 IgG antibody 59 metaglidasen 59 AAG geldanamycin analog 59 Randomized Double blind 59 fluvastatin 59 tolerability profile 59 octreotide 59 hypoglycemic events 59 Taxotere R 59 metastatic neuroendocrine tumors 59 Aurora kinase 58 FOLOTYN ® 58 primary hypercholesterolemia 58 GFT# 58 peg IFN 58 antibody MAb 58 Pharmacokinetics PK 58 Hypersensitivity reactions 58 hyperkalemia 58 pegylated interferons 58 relapsed refractory multiple myeloma 58 serum urate 58 Solid Tumors 58 receiving VELCADE 58 Cloretazine 58 bosentan 58 gastrointestinal toxicity 58 adrenal suppression 58 ACE inhibitor ramipril 58 Chemophase 58 Traficet EN 58 Hematologic 58 hepatic toxicity 58 aflibercept 58 piperacillin tazobactam 58 Pharmacokinetic 58 #mg/m# [002] 58 receiving golimumab 58 intravesical 58 basal bolus regimen 58 icatibant 58 Pharmacokinetic studies 58 baminercept 58 antiviral efficacy 58 oral FTY# 58 anthracycline containing 58 CYP #A# 58 LE DT 58 nilotinib Tasigna ® 58 carboplatin paclitaxel 58 refractory chronic lymphocytic 58 relapsed myeloma 58 Tarceva TM 58 Aclidinium 58 FOLFOX6 chemotherapy regimen 58 DMARD 58 RGB # 58 sensory neuropathy 58 insulin degludec 58 prednisone prednisolone plus 58 plus dexamethasone 58 alvimopan 58 1mg dose 58 monotherapy 58 Cleviprex TM clevidipine 58 BAY #-# 58 DermaVir Patch 58 CYC# 58 tipranavir r 58 AEG# 58 refractory acute myeloid 58 Ph + ALL 58 PegIFN 58 secondary efficacy endpoint 58 GATTEX ™ 58 oxycodone CR 58 XP# Transported Prodrug 58 anaphylactoid reactions 58 CORLUX CORT # 58 eritoran 58 AVE# 58 Hepatic Impairment 58 AKT inhibitor 58 linear pharmacokinetics 58 interferon gamma 1b 58 PEG IFN 58 endothelin antagonists 58 SCIg 58 tapentadol ER 58 calcineurin inhibitors 58 cobiprostone 58 r hGH 58 mcg dose 58 liposomal amphotericin B 58 nicardipine 58 tezampanel 58 sunitinib 58 vicriviroc 58 SCH # 58 elacytarabine 58 mucosal healing 58 Known hypersensitivity 58 serum phosphate levels 58 Forodesine HCl 58 DAS# remission 58 O PPDS 58 dose escalation phase 58 Tiotropium 58 Phase Ib clinical 58 CBLC# 58 clevidipine 58 nilotinib 58 CTA# Injection 58 MGCD# [001] 58 Akt activation 58 LATUDA 58 CLORETAZINE TM VNP#M 58 pulmonary toxicity 58 Scale EDSS 58 weekly subcutaneous injections 58 Sustained virologic response 58 Dose adjustments 58 thromboembolic 58 Adverse events 58 paricalcitol 58 fatigue asthenia 58 hyperalgesia 58 Infusion Reactions Severe 58 vWF 58 gemcitabine chemotherapy 58 relapsed MCL 58 Vicinium TM 58 double blinded placebo 58 adriamycin 58 zalutumumab 58 irinotecan containing 58 eltrombopag 58 CCR5 antagonist 58 ataluren 58 Melphalan 58 linaclotide treated 58 APTIVUS 58 budesonide foam 58 Tekamlo 58 hA# 58 AQ4N 58 thrombotic events 58 bortezomib Velcade 58 darinaparsin 58 HIV HCV coinfected 58 anaphylactic reactions bronchospasm 58 liver histology 58 Cethromycin 58 monoclonal antibody conjugated 58 lesinurad 58 ascending dose 58 Solid Tumors criteria 58 PNP inhibitor 58 Aliskiren 58 Secondary endpoints 58 Elvitegravir 58 CCX# B 58 interferon alfa 2a 58 HeFH 58 Malignant Glioma 58 μg dose 58 INFERGEN 58 dosing cohort 58 NATRECOR R 58 Hedgehog Pathway Inhibitor 58 metastatic HRPC 58 Altastaph 58 fosamprenavir 58 Blinatumomab 58 hemorrhagic cystitis 58 catheter occlusion 58 doxorubicin docetaxel 58 novel topoisomerase 58 pharmacokinetic characteristics 58 Amigal 58 pharmacodynamic 58 TOLAMBA 58 Navelbine 58 RoACTEMRA 58 recurrent malignant glioma 58 Panzem R 58 interstitial pneumonia 58 Peginterferon alfa 2b 58 long acting beta2 58 remission induction 58 myeloproliferative disorders 58 ruxolitinib 58 oral mTOR inhibitor 58 LB# [003] 58 secretory phospholipase A2 sPLA2 58 nucleoside analog 58 administered subcutaneously 58 ocrelizumab 58 Cimzia TM 58 MERLIN TIMI 58 LymphoStat B 58 anemia leukopenia 58 Belimumab 58 CrCl 58 PI3K/Akt pathway inhibitor 58 Flu Cy 58 APTIVUS ritonavir 58 KAPIDEX 58 TNF antagonists 58 metastatic castration resistant 58 conventional DMARDs 58 talabostat 58 TMC# r 58 sUA 58 Gleevec resistant 58 renal flares 58 lenalidomide Revlimid R 58 BAL# [002] 58 dose dependently 58 arbaclofen 58 xenograft models 58 Valortim ® 58 cannabinor 58 lomitapide 58 extrapyramidal symptoms EPS 57 Thrombotic events 57 pegylated interferon peg IFN 57 unresectable HCC 57 Hsp# Inhibitor 57 Zenvia ™ 57 symptomatic VTE 57 ancrod 57 aclidinium 57 LEXIVA r 57 potent triglyceride lowering 57 dopaminergic therapy 57 plasma uric acid 57 endometrial hyperplasia 57 cytotoxicity 57 transgene expression 57 mg kg BID 57 TRIOLEX HE# APOPTONE HE# 57 pharmacodynamics PD 57 bortezomib Velcade R 57 delayed CINV 57 EZN 57 gemcitabine cisplatin 57 imatinib 57 proliferative diabetic retinopathy 57 ON #.Na 57 oral methylnaltrexone 57 refractory indolent non 57 unknown etiology 57 dosed orally 57 evaluable 57 follicular lymphoma FL 57 Serious Adverse Events 57 recurrent NSCLC 57 PEGINTRON TM 57 Folfox 57 Tasigna prolongs 57 fondaparinux 57 anthracycline taxane 57 advanced carcinoid 57 oxcarbazepine 57 Telik logo TELINTRA 57 FOLFOX regimen 57 Cloretazine R 57 CRMD# 57 Amphinex ® 57 Peginterferon 57 Talactoferrin 57 abiraterone acetate 57 raltegravir 57 pegylated interferon alfa 57 p# activation 57 pseudobulbar affect PBA 57 Aplidin 57 evaluating picoplatin 57 Vidaza ® 57 nucleoside reverse transcriptase inhibitor 57 veltuzumab 57 R lenalidomide 57 MDS MPD 57 eculizumab 57 dose proportional pharmacokinetics 57 abacavir lamivudine 57 NEUMUNE 57 JAK inhibitors 57 Plicera 57 HER2 expression 57 immunotoxicity 57 ibandronate 57 docetaxel Taxotere R 57 nonclinical studies 57 palifosfamide 57 Natalizumab 57 Response Evaluation Criteria 57 R#/MEM # 57 Fidaxomicin 57 MEND CABG 57 NOXAFIL 57 Taxotere ® 57 virologic 57 KIACTA ™ 57 metastatic renal cell carcinoma 57 dexamethasone Decadron 57 eprotirome 57 primidone 57 TLK# 57 registrational trial 57 receptor inhibitor 57 confirmatory Phase III 57 Alocrest 57 IFN beta 57 Tyrima 57 hour bronchodilation 57 evaluable subjects 57 tapentadol IR 57 opioid bowel dysfunction 57 LHRH agonists 57 pharmacokinetic PK profile 57 PSN# [002] 57 milatuzumab 57 patients evaluable 57 ATACAND 57 androgen deprivation 57 huN# DM1 57 Index CDAI 57 cMET 57 L PPDS 57 taxane refractory 57 Hypokalemia 57 Ranolazine 57 S/GSK# 57 TNF antagonist 57 HIV RNA 57 unresectable 57 ACTEMRA 57 colesevelam HCl 57 Elocalcitol 57 rindopepimut 57 peg interferon 57 chronic HCV infection 57 solifenacin 57 R baclofen 57 pharmacodynamic profiles 57 ulimorelin 57 peginterferon alfa 2b 57 Antiviral Activity 57 DAVANAT 57 Elitek 57 mg/m2/day 57 nasopharyngitis headache 57 plus prednisone 57 Lenocta TM 57 IRX 2 57 elagolix 57 solithromycin 57 compound INCB# 57 comparator arm 57 mg dose 57 neratinib 57 Multimeric 57 SAR# [004] 57 amrubicin 57 NVA# 57 crizotinib PF # 57 GAMMAGARD 57 macrovascular events 57 diabetic neuropathic pain 57 efficacy tolerability 57 ascending doses 57 postoperative ileus POI 57 Serious adverse reactions 57 unfavorable cytogenetics 57 Phase III Pivotal 57 HGS# 57 PROCRIT 57 proton pump inhibitor PPI 57 Vandetanib 57 INTEGRILIN 57 TYGACIL 57 hypocalcemia 57 subgroup analyzes 57 β blockers 57 Subgroup analyzes 57 SinuNase 57 decitabine 57 Phase #/#a trial 57 XL# XL# XL# XL# 57 lipid lowering agents 57 irinotecan doxorubicin oxaliplatin paclitaxel 57 Sapacitabine 57 Peripheral edema 57 cardiac valvulopathy 57 GAMMAGARD LIQUID 57 IIIa inhibitor 57 TransVax ™ 57 hypersensitivity reactions 57 alkylating agents 57 statistically significant superiority 57 dyskinesia PD LID 57 subcutaneously administered 57 undetectable HBV DNA 57 EURIDIS 57 Eculizumab 57 Erythropoietic therapies may 57 CD4 monoclonal antibody 57 Hepatocellular Carcinoma HCC 57 INCB# [002] 57 Dextofisopam 57 oral prednisolone 57 mg/m2 57 selective agonist 57 extrapyramidal symptoms 57 Pharmacokinetic PK 57 mitoxantrone 57 ruboxistaurin 57 taxane resistant 57 hematologic 57 atacicept 57 Phase IIIb clinical 57 herpes zoster shingles 57 pegylated interferon alfa 2a 57 perifosine 57 radezolid 57 MADRS score 57 rNAPc2 57 virus HCV protease inhibitor 57 neutropenic fever 57 splenectomized patients

Back to home page